WELCOME to epgonline.org

Access trusted, independent sources of clinical content for the United Kingdom as well as other regions. Registration is quick and simple, providing you with unlimited access to all content and features.
 

Latest News

Added 1 day ago Drug news

Supplemental application for Tresiba (insulin degludec) in hypoglycaemia submitted to FDA- Novo Nordisk

Novo Nordisk has announced the submission of a supplemental application to the FDA for including data in the label for...

Added 1 day ago Drug news

FDA expands approval of Zykadia (ceritinib) to include patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase (ALK)-positive- Novartis

The FDA has approved the expanded use of Zykadia (ceritinib), from Novartis, to include the first-line treatment of patients with...

View all news articles

WHAT'S ON THE HORIZON?

Marshall Pearce

Cancer immunotherapies

Posted 1 month ago

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 1 month ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Latest Journal Abstracts

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.

Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments.

Added 22 hours ago

The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.

Introduction: Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poor effective. Several TKIs have been tested in clinical trials in pMTC patients.

Added 22 hours ago

Ponatinib in the therapy of chronic myeloid leukemia.

Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder that has become the neoplastic poster child for understanding the disease biology of a malignant disease and targeting effective therapy.

Added 23 hours ago

View all journal articles

Latest Guidelines

American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis.

The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees.

Added 3 months ago

GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD.

Since 2001, the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease has been a valuable resource for healthcare professionals.

Added 18 days ago

Psoriasis overview NICE Pathways

This document contains a single pathway diagram and uses numbering to link the boxes to the associated recommendations.

Added 3 months ago

View all guidelines

Latest Clinical Trials

Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

This study involves a course of radiation to up to 5 tumors in the participant's liver followed by systemic therapy (Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body).

Added 1 month ago

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

This is a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA)...

Added 3 months ago

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects (HS rPMS)

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Added 3 months ago

View all clinical trials